Evening Primrose Oil
Oenothera biennis
Evidence Rating
C Moderate
Confidence Level
Moderate
Medium (popularity significantly exceeds evidence strength)
Traditions
Western
Last Updated
2/9/2026
Summary
Evening Primrose Oil is one of the most widely used supplements for women's health, particularly for PMS and cyclical mastalgia. However, there is a notable gap between its consumer popularity and the strength of clinical evidence. The EMA/HMPC has granted only "traditional use" status, and only for dry skin conditions -- not for PMS or mastalgia. The active compound is gamma-linolenic acid (GLA), an omega-6 fatty acid precursor to anti-inflammatory prostaglandins. While some individual trials show positive results for mastalgia and PMS, systematic reviews and meta-analyses present mixed findings. The Cochrane review found insufficient evidence for atopic dermatitis. EPO represents a case where traditional reputation and consumer demand have outpaced scientific validation.
⚠️
Drug Interactions
This herb has significant drug interactions. Do not use if you are taking medications without consulting a healthcare provider first. See detailed interaction information below.
Regulatory Status
| Regulatory Body | Status |
|---|---|
| Commission E (Germany) | âś“ Approved |
| ESCOP (European) | âś“ Approved |
| EMA/HMPC (EU) | âś“ Approved |
Metadata
| Field | Detail |
|---|---|
| Common Names (English) | Evening Primrose Oil, EPO |
| Common Names (German) | Nachtkerzenoel, Nachtkerze |
| Botanical Name | Oenothera biennis L. (also O. lamarckiana) |
| Plant Family | Onagraceae |
| Part Used | Seed oil (Oenotherae oleum) |
| Evidence Quality Rating | Moderate — Traditional use only (EMA/HMPC); mixed clinical trial results for primary women’s health indications |
Approved Indications
Commission E (Germany)
- No positive monograph for PMS, mastalgia, or atopic dermatitis from Commission E
ESCOP
- No ESCOP monograph for PMS or mastalgia indications
- EPO has not been formally processed by ESCOP for these uses
EMA/HMPC
- Status: Traditional Use
- Indication: Relief of itching in short-term and long-term dry skin conditions
- Note: Traditional use means there is insufficient clinical evidence but plausibility of effectiveness and 30+ years of safe use (15+ years in EU)
- Specifically NOT approved for: PMS, mastalgia, or atopic dermatitis as herbal medicinal product indications
- Additional traditional indications noted: Mastodynia and cyclically recurring breast tension (mentioned in assessment but not as primary monograph indication)
WHO
- Recognizes EPO for atopic eczema, diabetic neuropathy, and mastodynia, though notes efficacy has not been sufficiently proven
Agreement/Disagreement Between Bodies
- Notable: No major European regulatory body has granted EPO formal approval for its most popular women’s health uses
- Gap: The traditional use status for dry skin is a much narrower indication than what consumers typically use EPO for
- Contrast with consumer use: EPO is marketed and used primarily for PMS and mastalgia, but regulatory endorsement for these uses does not exist
Conditions Treated
Marketed Uses (Popular but Variably Supported)
- Cyclical mastalgia / breast tenderness: Most evidence, but systematic reviews mixed
- Premenstrual syndrome (PMS): Some positive trials, but not consistently supported
- Atopic dermatitis / eczema: Cochrane review negative
EMA-Approved Traditional Use
- Dry skin conditions with itching: The only formally recognized indication
Investigated
- Menopausal hot flashes (limited evidence, one small trial negative)
- Diabetic neuropathy (some positive data, not women-specific)
- Cervical ripening in pregnancy (insufficient evidence)
- Rheumatoid arthritis (limited evidence)
Mechanism of Action
Specific Compounds
| Compound | Percentage in Oil | Role |
|---|---|---|
| Linoleic acid (LA) | 60-80% | Omega-6 essential fatty acid; precursor to GLA |
| Gamma-linolenic acid (GLA) | 8-14% | Key active compound; converted to DGLA and PGE1 |
| Oleic acid | ~7% | Minor component |
| Other fatty acids | ~5-10% | Palmitic, stearic acids |
Proposed Mechanism for Women’s Health
- GLA supplementation corrects a hypothesized deficiency in delta-6-desaturase activity
- GLA is converted to dihomo-gamma-linolenic acid (DGLA)
- DGLA is converted to prostaglandin E1 (PGE1) — an anti-inflammatory prostaglandin
- PGE1 modulates:
- Prolactin sensitivity in breast tissue (proposed mechanism for mastalgia)
- Inflammatory prostaglandin pathways (proposed mechanism for PMS)
- T-cell function and inflammatory mediators (proposed mechanism for atopic dermatitis)
Hypothesis: “Prostaglandin Deficiency Theory of PMS”
- Proposed by Horrobin (1983): PMS results from abnormal sensitivity to prolactin due to deficiency of PGE1
- GLA supplementation theoretically restores normal prostaglandin balance
- This hypothesis, while biochemically plausible, has not been definitively confirmed
Limitations of the Mechanism
- The conversion pathway (GLA -> DGLA -> PGE1) is influenced by many dietary and metabolic factors
- Supplemental GLA may not reliably increase PGE1 in all individuals
- The delta-6-desaturase deficiency hypothesis has not been conclusively demonstrated in PMS patients
Clinical Evidence Summary
Mastalgia
| Study/Review | Design | N | Finding |
|---|---|---|---|
| Pye et al. 1985 | Open trial | 291 | 45% response in cyclical mastalgia, 27% in non-cyclical |
| Gateley et al. 1992 | RCT | 72 | EPO 3g/day for 3 months: significant pain reduction in cyclical and non-cyclical |
| Blommers et al. 2002 | RCT, DB, PC | 120 | No significant difference vs. placebo for mastalgia |
| Srivastava et al. 2007 | RCT | 122 | EPO + Vitamin E superior to EPO alone and placebo |
| Meta-analysis (Defined et al. 2021, PMC) | Systematic review | Multiple | Priority of EPO over placebo confirmed in majority of studies |
Summary: Early open trials were promising. Controlled trials are mixed. A 2021 meta-analysis tentatively supports efficacy, but evidence quality is moderate at best.
PMS
| Study/Review | Design | N | Finding |
|---|---|---|---|
| Khoo et al. 1990 | RCT, DB, PC | 38 | Improvement in PMS severity scores |
| Puolakka et al. 1985 | RCT | 30 | Significant improvement |
| Budeiri et al. 1996 | RCT, DB, PC | 27 | No significant difference from placebo |
| Systematic reviews | Multiple | — | NCCIH concludes “no good scientific evidence” for PMS |
Summary: Some positive individual trials but systematic reviews do not support a consistent benefit for PMS.
Atopic Dermatitis / Eczema
- Cochrane Review (2013): Analyzed 19 studies; concluded EPO is NOT an effective treatment for eczema
- Contrasting evidence: A 2018 Korean RCT found significant improvement in skin dryness, pruritus, and lesion range
- Current consensus: Insufficient evidence to recommend
Menopausal Symptoms
- One small trial of gamolenic acid for menopausal flushing found no significant benefit vs. placebo
- Not a supported indication
European vs. US/Anglophone Consensus
| Aspect | European Consensus | US/Anglophone Consensus |
|---|---|---|
| Regulatory status | Traditional use only for dry skin (EMA); no Commission E approval for women’s health | Dietary supplement (FDA); no approved indications |
| PMS/mastalgia | Not formally endorsed; some clinicians use empirically | NCCIH: “no good scientific evidence” for PMS; some integrative MDs use |
| Eczema | License for Epogam (GLA product) was withdrawn in UK (2002) for lack of efficacy | Cochrane review: not effective |
| Consumer popularity | Very widely used despite limited evidence | Equally popular; widely available OTC |
| Professional opinion | Generally viewed with more skepticism in evidence-based phytotherapy circles | Mixed; some naturopathic support |
Safety Profile
Contraindications
- Known hypersensitivity to EPO or Onagraceae
- Seizure disorders: Precautionary avoidance in epilepsy (historical concern, largely debunked — see below)
- Bleeding disorders: Theoretical antiplatelet activity; avoid before surgery
Drug Interactions
- Anticoagulants/antiplatelets (warfarin, aspirin, clopidogrel): Theoretical increased bleeding risk
- Phenothiazines (chlorpromazine, etc.): Historical reports of seizures when EPO given with phenothiazines in schizophrenic patients — however, these patients had pre-existing seizure history and the association was spurious per re-analysis
- Anesthesia: Discontinue 2 weeks before elective surgery (theoretical bleeding risk)
- Cyclosporine: Possible synergistic anti-inflammatory effects [UNCERTAIN]
The Seizure Concern: History and Resolution
- Origin: Two case reports in the early 1980s involving schizophrenic patients on phenothiazines
- Re-analysis: The association with seizures has been shown to be spurious; all affected patients had pre-existing seizure risk factors
- 2007 safety review: Concluded EPO does not cause epilepsy; safety in epilepsy patients confirmed
- Current position: No longer considered a true contraindication, but precautionary warnings persist in some product labeling
Side Effects
- Gastrointestinal: nausea, soft stools, diarrhea, bloating (most common)
- Headache (occasional)
- Generally very well tolerated at standard doses
- No serious adverse events reported in clinical trials
Pregnancy and Lactation
- Pregnancy: Not recommended — insufficient safety data; some traditional use for cervical ripening is NOT supported by evidence
- Lactation: Likely safe in dietary amounts; insufficient data for supplemental doses
- Cervical ripening: Some midwives recommend EPO in late pregnancy, but this is NOT evidence-based and is NOT endorsed by regulatory bodies [CONTESTED]
Clinical Dosage
Recommended Forms and Doses
| Indication | GLA Dose | Total EPO Dose | Duration |
|---|---|---|---|
| Mastalgia (cyclical) | 240-320 mg GLA/day | 2,000-3,000 mg/day | 3-6 months |
| PMS | 180-270 mg GLA/day | 2,000-3,000 mg/day | 3-4 cycles |
| Dry skin (EMA traditional use) | 160-320 mg GLA/day | 2,000-4,000 mg/day | As needed |
| Atopic dermatitis | 320-480 mg GLA/day | 4,000-6,000 mg/day | 8-12 weeks (if attempted) |
Key Considerations
- GLA content varies by product: Always calculate based on GLA content, not total oil volume
- Typical capsule: 500 mg or 1000 mg EPO, containing 40-50 mg or 80-100 mg GLA respectively
- Higher doses needed for dermatological conditions than for gynecological ones
- Minimum treatment duration: 8-12 weeks to assess response (fatty acid incorporation takes time)
Key Products
- Efamol (historical): One of the original standardized EPO products
- Epogam (UK, historical): Was licensed for atopic eczema; license withdrawn 2002 for insufficient efficacy evidence
- Generic EPO capsules are widely available; quality (GLA content) varies
Connections
- Compare with Vitex Chasteberry for mastalgia — Vitex has stronger evidence and a clearer mechanism (prolactin reduction)
- Safety profile is relevant to the cross-cutting anticoagulant interaction theme across several herbs